尿激酶受体
癌症研究
衰老
生物
表型
受体
医学
免疫学
内科学
细胞生物学
基因
遗传学
作者
Corina Amor,Inés Fernández-Maestre,Saria Chowdhury,Yu-Jui Ho,Sandeep Nadella,Courtenay Graham,Sebastian E. Carrasco,Emmanuella Nnuji-John,Judith Feucht,Clemens Hinterleitner,Valentin J.A. Barthet,Jacob A. Boyer,Riccardo Mezzadra,Matthew G. Wereski,David A. Tuveson,Ross L. Levine,Lee W. Jones,Michel Sadelain,Scott W. Lowe
出处
期刊:Nature Aging
[Nature Portfolio]
日期:2024-01-24
卷期号:4 (3): 336-349
被引量:245
标识
DOI:10.1038/s43587-023-00560-5
摘要
Abstract Senescent cells accumulate in organisms over time because of tissue damage and impaired immune surveillance and contribute to age-related tissue decline1,2. In agreement, genetic ablation studies reveal that elimination of senescent cells from aged tissues can ameliorate various age-related pathologies, including metabolic dysfunction and decreased physical fitness3-7. While small-molecule drugs capable of eliminating senescent cells (known as ‘senolytics’) partially replicate these phenotypes, many have undefined mechanisms of action and all require continuous administration to be effective. As an alternative approach, we have developed a cell-based senolytic therapy based on chimeric antigen receptor (CAR) T cells targeting uPAR, a cell-surface protein upregulated on senescent cells, and previously showed these can safely and efficiently eliminate senescent cells in young animals and reverse liver fibrosis8. We now show that uPAR-positive senescent cells accumulate during physiological aging and that they can be safely targeted with senolytic CAR T cells. Treatment with anti uPAR CAR T cells ameliorates metabolic dysfunction by improving glucose tolerance and exercise capacity in physiological aging as well as in a model of metabolic syndrome. Importantly, a single administration of a low dose of these senolytic CAR T cells is sufficient to achieve long-term therapeutic and preventive effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI